News | Ventricular Assist Devices (VAD) | May 22, 2019

Impella SmartAssist Platform Launches at SCAI

Majority of Impella CP heart pumps in U.S. will be transitioned to SmartAssist over next fiscal year

Impella SmartAssist Platform Launches at SCAI

May 22, 2019 — Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions, May 19-22 in Las Vegas, through a controlled launch process at select sites. The majority of Impella CP heart pumps in the U.S. will be transitioned to SmartAssist over the next fiscal year.

Abiomed received U.S. Food and Drug Administration (FDA) approval for Impella CP with SmartAssist in March 2018. The device is designed to improve patient outcomes with advanced algorithms and simplified patient management. During a limited market release over the past year, more than 1,000 patients at 70 sites have been treated with the SmartAssist platform. These advances in Impella forward-flow heart pump technologies and software are designed to improve ease-of-use and patient management to optimize both survival and heart recovery:

  • Weaning algorithms to optimize survival and native heart recovery: Real-time displays of critical hemodynamic metrics including left ventricular end-diastolic pressure (LVEDP), mean arterial pressure (MAP) and cardiac power output (CPO). Impella CP with SmartAssist is the only mechanical circulatory support device, according to Abiomed, that calculates and displays LVEDP, MAP and CPO.
  • Easier management and repositioning: SmartAssist sensor allows for precise positioning in the aorta and left ventricle and repositioning in the intensive care unit (ICU) without the need for catheterization lab or ultrasound imaging.
  • Greater hemodynamic support: Allows for sustained peak flows of up to 4.3L/minute (>85 percent of a normal cardiac cycle).
  • Faster, simplified Impella console setup: Less than 90 seconds.

“Access to real-time clinical data has allowed our team to identify best practices for patient management and weaning,” said Hiram Bezerra, interventional cardiologist, University Hospitals, Cleveland, and a participant in the limited market release. “Metrics such as LVEDP, MAP and CPO and the ability to monitor trends on the Impella console allow physicians to utilize this hemodynamic information to optimize heart recovery with objective and quantifiable data to enable clear communication within the shock team.”

The SmartAssist platform is complemented by Abiomed’s on-site and on-call support, including the Clinical Support Center, which provides 24/7 expert evaluation of Impella data and collaborative patient care to help improve outcomes.

Read the article "FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor"

For more information: www.abiomed.com

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Overlay Init